| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Milestone Pharmaceuticals Inc (NASDAQ: MIST)
MIST Technical Analysis
5
| As on 28th Mar 2025 MIST STOCK Price closed @ 0.88 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.84 & Strong Sell for SHORT-TERM with Stoploss of 2.74 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MISTSTOCK Price
| Open | 0.76 | Change | Price | % |
| High | 0.97 | 1 Day | -1.37 | -60.89 |
| Low | 0.75 | 1 Week | -1.11 | -55.78 |
| Close | 0.88 | 1 Month | -1.41 | -61.57 |
| Volume | 33148006 | 1 Year | -2.06 | -70.07 |
| 52 Week High 3.39 | 52 Week Low 1.29 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| LXRX | 0.57 | 62.86% |
| NVDA | 109.67 | -1.58% |
| SNSE | 0.51 | 18.60% |
| TSLA | 263.55 | -3.51% |
| LMDX | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| LILM | 0.05 | -79.17% |
| PONO | 1.72 | 2.38% |
| TELL | 1.00 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MIST Daily Charts |
MIST Intraday Charts |
Whats New @ Bazaartrend |
MIST Free Analysis |
|
|
MIST Important Levels Intraday
| RESISTANCE | 1.30 |
| RESISTANCE | 1.17 |
| RESISTANCE | 1.08 |
| RESISTANCE | 1.00 |
| SUPPORT | 0.76 |
| SUPPORT | 0.68 |
| SUPPORT | 0.59 |
| SUPPORT | 0.46 |
MIST Forecast March 2025
| 4th UP Forecast | 4.54 |
| 3rd UP Forecast | 3.37 |
| 2nd UP Forecast | 2.64 |
| 1st UP Forecast | 1.92 |
| 1st DOWN Forecast | -0.16 |
| 2nd DOWN Forecast | -0.88 |
| 3rd DOWN Forecast | -1.61 |
| 4th DOWN Forecast | -2.78 |
MIST Weekly Forecast
| 4th UP Forecast | 1.75 |
| 3rd UP Forecast | 1.47 |
| 2nd UP Forecast | 1.30 |
| 1st UP Forecast | 1.13 |
| 1st DOWN Forecast | 0.63 |
| 2nd DOWN Forecast | 0.46 |
| 3rd DOWN Forecast | 0.29 |
| 4th DOWN Forecast | 0.01 |
MIST Forecast2025
| 4th UP Forecast | 6.22 |
| 3rd UP Forecast | 4.51 |
| 2nd UP Forecast | 3.45 |
| 1st UP Forecast | 2.39 |
| 1st DOWN Forecast | -0.63 |
| 2nd DOWN Forecast | -1.69 |
| 3rd DOWN Forecast | -2.75 |
| 4th DOWN Forecast | -4.46 |
Milestone Pharmaceuticals Inc ( NASDAQ USA Symbol : MIST )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MIST Business Profile
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China. The company was incorporated in 2003 and is headquartered in Montréal, Canada. Address: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service